Wendy Phillips
Senior Medical Physicist

John Lawson
Acting Chief Physicist

Paul Reich
Acting Principal Physicist
Royal Adelaide Hospital

Purpose: This study provides an overview of the changes in brachytherapy services at the RAH over the past decade. Data on patient numbers, treatment techniques, treatment procedure times and staff requirements have been collected and presented to enable a review of the service development over this time-frame.

Methods: Data has been collected and analysed on a per annum basis for all of the HDR and LDR brachytherapy treatments that were delivered at the RAH from 2006 to 2016. This includes the commonly treated sites such as HDR prostate and HDR gynaecological to the less common treatments such as LDR eye plaques and HDR surface moulds. Statistics presented include patient numbers and treatment fraction numbers delivered, separated into treatment technique. Average staff number requirements, in terms of professional roles, and average treatment procedural times for each type of case are also discussed for the busy brachytherapy workload of this institution.

Results: Results will be presented in detail on the variety of treatments undertaken. In brief, patient referrals have continuously increased in number over the past 10 years, for example in 2006 HDR prostate cases numbered 11; while 2016 saw 77 patients treated. The HDR prostate service has also involved over the years from a 2 fraction boost treatment to either a single fraction boost, single fraction mono-therapy, or single fraction salvage therapy treatment. HDR vaginal cylinder treatments have been the most commonly treated technique, rising from 90 to over 230 treatment fractions delivered per year, over the 10 years studied. In this multidisciplinary clinical field, an experienced and dedicated team is vital, with current staff involvement ranging from 4 staff members for a simple HDR vaginal cylinder gynaecology case, to 9 staff members for a HDR intrauterine gynaecology treatment session.

Summary: The RAH brachytherapy program is extremely diverse and growing each year. It is currently the sole provider of HDR services for SA/NT and provides key treatment options as either a sole or combination radiotherapy treatment (boost) to external beam therapy. With the move to the new RAH in 2017, it is envisaged that the RAH brachytherapy program will continue to expand and develop while delivering this vital service to patients.

(Poster presentation)

← Back to all abstracts